Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

T-794: a MAO-A inhibitor with antidepressant activity

April 20, 1998

Phase I data reported on CoCensys' ganaxolone tablet formulation

April 17, 1998

Allelix gets go-ahead to start U.K. trials for antimigraine drug

April 17, 1998

OGS and Pfizer to collaborate on Alzheimer's disease research

April 17, 1998

Ampligen to be evaluated in U.S. phase III trials for chronic fatigue syndrome

April 17, 1998

Novel dopaminergic compounds in the pipeline at ADIR

April 17, 1998

Another H3 antagonist in the pipeline at Gliatech

April 16, 1998

DuPont Merck presents a novel CRF-R1 antagonist for anxiety and depression

April 16, 1998

Meiji Seika presents 5-HT7 antagonist DR-4004

April 16, 1998

Kynurenine 3-monooxygenase inhibitors under study at P&U as neuroprotectants

April 16, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Sumitomo’s DSP-3456 exerts antidepressant-like effects
BioWorld Science
About one-third of patients with major depressive disorder (MDD) are treatment resistant. Ketamine is very effective in treatment-resistant depression, but it is...